-
1.发明专利
公开(公告)号：GB2464028B
公开(公告)日：2011-06-01
申请号：GB201000660
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
-
公开(公告)号：GB2460966A
公开(公告)日：2009-12-23
申请号：GB0913559
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： HUANG CHUN-YUNG , LIANG SHU-MEI
Abstract: An isolated protein comprising an RGD motif and having a fibrillar structure, for use in medicine, is disclosed. The RGD-containing protein is preferably fibronectin, and may be used in the treatment of cancer, particularly kidney, breast, lung or ovarian cancer. The protein may induce cell death by modulating an Akt signaling pathway. The protein may also be used as an adjuvant.
-
3.发明专利
公开(公告)号：GB2464028A
公开(公告)日：2010-04-07
申请号：GB201000660
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: An isolated fibrillar structure protein of the foot-and-mouth-disease virus, selected from recombinant capsid protein VP1 (rVP1), recombinant capsid protein VP2 (rVP2), recombinant capsid protein VP3 (rVP3), precursor protein P1 of VP1, VP2, VP3 and VP4, or a chimeric protein comprising parts of at least two proteins selected from VP1, VP2, VP3 or VP4. Also disclosed is the use of this isolated fibrillar structure protein of the foot-and-mouth-disease virus in medicine, in particular in the treatment of cancer, and a pharmaceutical composition comprising said protein.
-
公开(公告)号：GB2460283A
公开(公告)日：2009-11-25
申请号：GB0809919
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, and applying the solution to a molecular sizing column with a pore size of at least 70 kDa. The column is preferably selected from a SuperdexRTM200 or a HW555, and the detergent is preferably selected from SDS or Zwittergent 3-14. The globular protein is preferably selected from albumin, fibronectin or recombinant capsid proteins VP1, VP2, or VP3 of the foot and mouth disease virus, or precursor or chimeric proteins thereof. The proteins may have a use in medicine, particularly in the treatment of cancer, or they may be used as vaccine adjuvants.
-
公开(公告)号：GB2460965A
公开(公告)日：2009-12-23
申请号：GB0913558
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG
Abstract: An isolated fibrillar albumin for use in medicine is disclosed. The albumin may be used in the treatment of cancer, particularly kidney, breast, lung or ovarian cancer, and induces cell death by modulating an Akt signalling pathwat. Alternatively the fibrillar albumin may be used as an adjuvant.
-
Patent Agency Ranking
公开(公告)号：GB2460966B
公开(公告)日：2010-05-19
申请号：GB0913559
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： HUANG CHUN-YUNG , LIANG SHU-MEI , LIANG CHI-MING
Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
-
公开(公告)号：GB2460965B
公开(公告)日：2010-05-19
申请号：GB0913558
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG
Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
-
公开(公告)号：GB2460283B
公开(公告)日：2010-04-21
申请号：GB0809919
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
-
9.发明申请PROCESS TO PRODUCE FIBRILLAR PROTEINS AND METHOD OF TREATING USING FIBRILLAR PROTEINS 审中-公开生产纤维蛋白蛋白的方法和使用纤维蛋白蛋白的治疗方法
公开(公告)号：WO2009114831A3
公开(公告)日：2009-10-22
申请号：PCT/US2009037196
申请日：2009-03-13
Applicant: ACADEMIA SINICA , LIANG SHU MEI , LIANG CHI-MING , CHEN YEN-PO , HUANG CHUN-YUNG
Inventor： LIANG CHI-MING , CHEN YEN-PO , HUANG CHUN-YUNG
CPC classification number: C07K1/1136 , A61K38/162 , A61K38/38 , A61K38/39 , C07K14/765 , C07K14/78 , C12N2770/32122 , C12N2770/32151
Abstract: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof. A method for producing a vaccine adjuvant or antigen adjuvant comprising the steps of providing a protein, and changing the protein into a fibrillar structure.
Abstract translation: 一种将球状蛋白质结构变为纤维状蛋白质结构的方法。 该方法包括以下步骤：提供球状蛋白质，形成含有球状蛋白质的溶液，向含有球状蛋白质的溶液中加入去污剂，将该溶液应用于孔径至少为70kDa的分子筛分柱，并用 含有清洁剂的溶液。 一种将未折叠的蛋白质结构变为纤维状蛋白质结构的方法。 该方法包括以下步骤：提供球状蛋白质，形成含有球状蛋白质的溶液，向溶液中加入尿素以展开球状蛋白质，将溶液施加到分子大小柱上并用含有去污剂的溶液洗脱。 一种治疗癌症的方法，包括以下步骤：提供蛋白质，将蛋白质变为纤维状结构，并将治疗有效量的纤维状结构蛋白给予有需要的患者。 生产疫苗佐剂或抗原佐剂的方法，包括提供蛋白质和将蛋白质变成纤维状结构的步骤。
-
10.发明公开PROCESS TO PRODUCE FIBRILLAR PROTEINS AND METHOD OF TREATING USING FIBRILLAR PROTEINS 有权用于生产类纤维蛋白和采用纤维状蛋白的治疗方法
公开(公告)号：EP2262825A4
公开(公告)日：2012-12-26
申请号：EP09719402
申请日：2009-03-13
Applicant: ACADEMIA SINICA
Inventor： LIANG CHI-MING , HUANG CHUN-YUNG
IPC: C07K1/107 , A61K38/16 , A61K38/17 , A61K38/38 , A61K38/39 , A61P35/00 , C07K1/14 , C07K14/09 , C07K14/47 , C07K14/765 , C07K14/78
CPC classification number: C07K1/1136 , A61K38/162 , A61K38/38 , A61K38/39 , C07K14/765 , C07K14/78 , C12N2770/32122 , C12N2770/32151
Abstract: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof. A method for producing a vaccine adjuvant or antigen adjuvant comprising the steps of providing a protein, and changing the protein into a fibrillar structure.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
